Sino Biopharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Sino Biopharmaceutical heeft een totaal eigen vermogen van CN¥42.8B en een totale schuld van CN¥9.6B, wat de schuld-eigenvermogensverhouding op 22.4% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥65.4B en CN¥22.6B. De EBIT Sino Biopharmaceutical is CN¥5.8B waardoor de rentedekking -5.5 is. Het heeft contanten en kortetermijnbeleggingen van CN¥14.8B.

Belangrijke informatie

22.44%

Verhouding schuld/eigen vermogen

CN¥9.60b

Schuld

Rente dekkingsratio	-5.5x
Contant	CN¥14.82b
Aandelen	CN¥42.77b
Totaal verplichtingen	CN¥22.63b
Totaal activa	CN¥65.41b

Recente financiële gezondheidsupdates

Recent updates

Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

May 06

Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Apr 30

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Apr 27

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Apr 06

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Mar 23

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Jan 13

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Dec 08

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥24.7B ) 1177 } overtreffen de korte termijn passiva ( CN¥19.6B ).

Langlopende schulden: De kortetermijnactiva 1177 ( CN¥24.7B ) overtreffen de langetermijnschulden ( CN¥3.1B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 1177 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1177 is de afgelopen 5 jaar gedaald van 41.6% naar 22.4%.

Schuldendekking: De schuld van 1177 wordt goed gedekt door de operationele kasstroom ( 68.9% ).

Rentedekking: 1177 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/21 04:28
Aandelenkoers aan het einde van de dag	2025/05/21 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Sino Biopharmaceutical Limited wordt gevolgd door 54 analisten. 23 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Ling Zhang	BNP Paribas Securities (Asia)
Justin Liu	BNP Paribas Securities (Asia)
Sharon Shi	BOCI Research Ltd.

Sino Biopharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Recent updates

Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Biopharmaceutical Limited Announces Application for Clinical Trial of "TQB3019 (BTK PROTAC)" Approved by NMPA

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Sino Biopharmaceutical Limited Announces Approval for Clinical Trial of TQB2101 (RR1 ADC)

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Culmerciclib in Combination with Fulvestrant for First-Line Treatment of H-Positive and HER2-Negative Breast Cancer

Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04

Final dividend of HK$0.04 announced

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 10, 2025

Sino Biopharmaceutical Limited Announces Publication of Results from Phase Ib/IIa Clinical Study of "Rovadicitinib"

Sino Biopharmaceutical Limited to Report Fiscal Year 2024 Results on Mar 20, 2025

Sino Biopharmaceutical Limited Announces Approval for Marketing of the First Generic Tulobuterol Patches

Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult

Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy

Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma

Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold HK$51m worth of stock

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

First half 2024 earnings: EPS and revenues exceed analyst expectations

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

Consensus EPS estimates increase by 11%

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Investor sentiment improves as stock rises 18%

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Consensus revenue estimates fall by 13%

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield